Summit Therapeutics shares traded higher as the market reacted to fresh attention on updated Phase III ivonescimab data being presented at the European Lung Cancer Congress (ELCC) 2026. The company’s ELCC lineup put a spotlight on outcomes in tougher-to-treat advanced non-small cell lung cancer populations, including patients with baseline brain metastases—an area investors often view as a key differentiator for immuno-oncology regimens. (smmttx.com)

One ELCC poster from the Phase III HARMONi study focuses on intracranial outcomes for EGFR-mutated, TKI-resistant NSCLC and includes patients with and without asymptomatic brain metastases at baseline. In the subset with baseline brain metastases, intracranial progression-free survival was described at 10.1 months for ivonescimab plus chemotherapy versus 6.5 months for chemotherapy (HR 0.53; nominal p=0.0068), helping frame the day’s bullish tone. (sahmcapital.com)

SMMT remains a catalyst-driven oncology name where clinical efficacy narratives can quickly influence expectations for regulatory outcomes and commercial potential. With the FDA having accepted Summit’s BLA for ivonescimab in NSCLC and set a PDUFA date of November 14, 2026, investors are increasingly sensitive to any data that supports differentiation in high-need subpopulations, including CNS disease. (finance.yahoo.com)